A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 29 Apr 2014 Planned end date changed from 1 Jan 2014 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 12 Jun 2013 Planned end date changed from 1 Jun 2011 to 1 Jan 2014 as reported by ClinicalTrials.gov.